Powered by

ProMIS Neurosciences Issues Year-to-Date Update, Highlighting 2018 Accomplishments

Nov 20, 2018 - Thomson Reuters ONE

Development of therapeutic antibodies for Alzheimer's disease, Parkinson's disease and ALS are top priorities for drug development and potential partnering

TORONTO and CAMBRIDGE, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today issued a narrated year-to-date overv...